biopharmaceutical

Vera Therapeutics appoints Christopher Hite, Royalty Pharma EVP, to board as the biotech prepares for atacicept launch in IgA nephropathy treatment.

Oculis plans March 2026 investor conferences highlighting six pivotal clinical readouts, including Privosegtor's breakthrough optic neuritis program and OCS-01 Phase 3 results expected Q2 2026.

Oculis announces March 2026 investor conference participation, showcasing pipeline advances including Privosegtor's optic neuritis breakthrough designation and anticipated Phase 3 readouts.

Oculis files 2025 audited financial statements with SEC via Form 20-F and announces investor conference participation, signaling transparent capital markets engagement.

Clinical-stage biotech $SVRA will present at 2026 Citizens Life Sciences Conference, showcasing progress on its Phase 3 rare respiratory disease program.

Palvella Therapeutics closed $230M public offering at $125/share on February 27, 2026, fully exercising underwriter options to fund rare skin disease programs.

MacroGenics to participate in four major healthcare investor conferences in March 2026, with management presenting on pipeline developments and business operations.

Bicara Therapeutics raises $172.5M in oversubscribed offering, with proceeds funding development of lead immunotherapy candidate ficerafusp alfa for solid tumors.

Palvella Therapeutics raised $200M through upsized share offering to fund clinical development of rare disease therapies including skin disease and vascular malformation treatments.

GSK acquires 35Pharma for $950M, adding pulmonary hypertension treatment HS235 to its pipeline. Move strengthens GSK's position in the growing $18B market.

EyePoint will report 2025 results March 4, highlighting pipeline progress. Lead drug DURAVYU™ advances toward Phase 3 trials for retinal diseases with key data expected mid-2026.

Immuron lifted H1 revenue 5% to AUD$4.2M with strong U.S. growth of 17%. The company secured AUD$7.3M funding and is pursuing partnerships to advance its clinical pipeline.

GSK acquires 35Pharma for $950M to gain HS235, a clinical-stage pulmonary hypertension drug with improved safety profiles versus existing treatments.

Bicara Therapeutics plans $150M stock offering to advance its lead drug candidate ficerafusp alfa through clinical development and build commercial infrastructure for potential market launch.

Day One Biopharmaceuticals reports 172% revenue growth to $155.4M, driven by OJEMDA sales strength. Company acquires Mersana Therapeutics to expand pipeline.

Autolus to present pipeline updates and 2025 financial results at two March 2026 healthcare conferences, discussing commercial progress and strategic priorities.

Supernus Pharmaceuticals will present at three major healthcare conferences in March 2026, updating investors on strategic initiatives and operational progress.

Palvella to present Phase 3 SELVA trial results for QTORIN gel treating lymphatic malformations on February 24, 2026, with data release at 6:30 a.m. ET.

Apellis will discuss its complement-targeted drug portfolio at TD Cowen Healthcare Forum in March 2026, highlighting its approved therapies for eye and kidney diseases.

Candel Therapeutics raises $100M via public share offering to fund commercialization of its prostate cancer gene therapy and ongoing lung cancer clinical trials.